The Fort Worth Press - Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

USD -
AED 3.672504
AFN 65.503991
ALL 81.893517
AMD 377.703986
ANG 1.79008
AOA 917.000367
ARS 1431.463704
AUD 1.424075
AWG 1.8
AZN 1.70397
BAM 1.658906
BBD 2.014216
BDT 122.30167
BGN 1.67937
BHD 0.377004
BIF 2963.603824
BMD 1
BND 1.273484
BOB 6.910269
BRL 5.23885
BSD 1.000025
BTN 90.583306
BWP 13.239523
BYN 2.873016
BYR 19600
BZD 2.011247
CAD 1.36432
CDF 2230.000362
CHF 0.775404
CLF 0.021785
CLP 860.180396
CNY 6.93805
CNH 6.93014
COP 3691.11
CRC 495.76963
CUC 1
CUP 26.5
CVE 93.526553
CZK 20.49104
DJF 177.720393
DKK 6.318604
DOP 63.114413
DZD 129.915817
EGP 46.860804
ERN 15
ETB 155.46494
EUR 0.84612
FJD 2.209504
FKP 0.738005
GBP 0.734505
GEL 2.69504
GGP 0.738005
GHS 10.990102
GIP 0.738005
GMD 73.000355
GNF 8778.001137
GTQ 7.670255
GYD 209.225001
HKD 7.81355
HNL 26.416279
HRK 6.375104
HTG 131.004182
HUF 319.673504
IDR 16847.65
ILS 3.110675
IMP 0.738005
INR 90.60355
IQD 1310.041816
IRR 42125.000158
ISK 122.690386
JEP 0.738005
JMD 156.517978
JOD 0.70904
JPY 157.06304
KES 129.004623
KGS 87.450384
KHR 4035.7261
KMF 419.00035
KPW 900.002243
KRW 1462.730383
KWD 0.30717
KYD 0.833355
KZT 494.785725
LAK 21489.944613
LBP 89557.410282
LKR 309.387392
LRD 188.003087
LSL 16.133574
LTL 2.95274
LVL 0.60489
LYD 6.332646
MAD 9.180641
MDL 17.050476
MGA 4439.468349
MKD 52.169828
MMK 2100.00747
MNT 3580.70414
MOP 8.047618
MRU 39.542143
MUR 46.060378
MVR 15.450378
MWK 1734.055998
MXN 17.260975
MYR 3.947504
MZN 63.750377
NAD 16.133574
NGN 1367.390377
NIO 36.803155
NOK 9.658735
NPR 144.932675
NZD 1.659792
OMR 0.384466
PAB 1.000025
PEN 3.364787
PGK 4.288489
PHP 58.458038
PKR 279.633919
PLN 3.568365
PYG 6607.462446
QAR 3.645108
RON 4.308404
RSD 99.305038
RUB 77.002259
RWF 1459.579124
SAR 3.750159
SBD 8.058149
SCR 13.731545
SDG 601.503676
SEK 9.004245
SGD 1.271104
SHP 0.750259
SLE 24.450371
SLL 20969.499267
SOS 570.497977
SRD 37.818038
STD 20697.981008
STN 20.780851
SVC 8.750011
SYP 11059.574895
SZL 16.130113
THB 31.539504
TJS 9.370298
TMT 3.505
TND 2.900328
TOP 2.40776
TRY 43.592904
TTD 6.771984
TWD 31.613038
TZS 2575.000335
UAH 42.955257
UGX 3558.190624
UYU 38.652875
UZS 12280.366935
VES 377.985125
VND 25950
VUV 119.988021
WST 2.726314
XAF 556.381418
XAG 0.012857
XAU 0.000201
XCD 2.70255
XCG 1.802328
XDR 0.692248
XOF 556.381418
XPF 101.156094
YER 238.403589
ZAR 16.024104
ZMK 9001.203584
ZMW 18.62558
ZWL 321.999592
  • SCS

    0.0200

    16.14

    +0.12%

  • RBGPF

    0.1000

    82.5

    +0.12%

  • AZN

    5.8700

    193.03

    +3.04%

  • GSK

    1.0600

    60.23

    +1.76%

  • NGG

    1.1700

    88.06

    +1.33%

  • BTI

    0.8400

    62.8

    +1.34%

  • CMSC

    -0.0400

    23.51

    -0.17%

  • CMSD

    0.0600

    23.95

    +0.25%

  • BP

    0.8400

    39.01

    +2.15%

  • RIO

    2.2900

    93.41

    +2.45%

  • BCE

    -0.4900

    25.08

    -1.95%

  • JRI

    0.0900

    12.97

    +0.69%

  • RELX

    -0.7100

    29.38

    -2.42%

  • RYCEF

    0.2600

    16.88

    +1.54%

  • BCC

    1.8700

    91.03

    +2.05%

  • VOD

    0.4900

    15.11

    +3.24%

Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy
Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

TAMPA, FLORIDA / ACCESS Newswire / August 14, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the termination of its equity purchase agreement ("ELOC") with Hudson Global Ventures, LLC.

Text size:

The ELOC was an effective tool that nearly doubled the Company's original IPO raise. The decision to terminate the agreement reflects a strategic shift toward accretive financing and reinforces its aim of long-term shareholder value creation.

Management cited strong execution in expanding its independent pharmacy network, accelerating adoption of its AI-powered prescription routing technology and payment platforms, and creating a strong pipeline for growth opportunities with manufacturer direct-to-patient (DTP) platforms as drivers behind the move. This unique approach is designed to bypass traditional PBM barriers, increase manufacturer margins, and accelerate patient access.

"From a financial standpoint, terminating the ELOC aligns with our disciplined approach to capital structure and shareholder equity preservation," said Mark DiSiena, Chief Financial Officer of Wellgistics Health. "It allows us to secure more favorable funding opportunities so we can focus on our strategic plans, optimize our cost of capital, and pursue options that better reflect our growth trajectory."

"This decision reflects the discipline we're bringing to every part of the business," said Brian Norton, Chief Executive Officer of Wellgistics Health. "We've moved past the challenges of our opening quarters and are entering a new chapter built on operational strength and strategic execution. We're ready to show the market what we're truly capable of - delivering smarter, faster access to medicine, empowering independent pharmacies, and creating lasting value across the healthcare ecosystem."

About Wellgistics Health

Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ independent pharmacies and 200+ U.S. manufacturers, providing wholesale distribution, digital prescription routing, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health offers compliant, end-to-end solutions that restore access, transparency, and trust in U.S. healthcare.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, market conditions and other risks detailed in our reports and statements filed with the SEC. Investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Media Contact: [email protected]

Investor Relations: [email protected]

Investor Relations Contact:

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

G.Dominguez--TFWP